Prodia StemCell Indonesia Report issue

For profit Phase 2 Phase 3
Founded: jakarta Indonesia (1973)

Organization Overview

First Clinical Trial
2018
NCT04357600
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Prodia Stem Cell Indonesia | Prodia StemCell Indonesia | PT. Prodia Stem Cell Indonesia

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Palsy (Phase 2)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis B (Phase 2)

Infarction (Phase 2)

Keloid (Phase 2)

Liver Cirrhosis (Phase 2)

Myocardial Infarction (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Paralysis (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4